Quanterix Corporation reported its financial results for the third quarter of 2025, revealing a total revenue of $40.2 million, a 12% increase from $35.8 million in the same period last year. The growth was primarily driven by a 33% rise in product revenue, which reached $26.2 million, largely attributed to the acquisition of Akoya Biosciences, which contributed $11.3 million in product sales. However, the legacy Quanterix business experienced a decline of $4.8 million, or 25%, due to reduced demand from academic customers and macroeconomic challenges affecting pharmaceutical research and development spending.
Despite the revenue increase, Quanterix reported a net loss of $33.5 million for the quarter, compared to a loss of $8.4 million in the prior year. This significant increase in losses was influenced by a rise in operating expenses, which surged by 71% to $54.5 million, driven by higher selling, general, and administrative costs, including $7.4 million in acquisition-related expenses from the Akoya merger. Additionally, the company incurred $7.2 million in impairment and restructuring costs related to workforce reductions and the impairment of a leased facility.
Operationally, Quanterix's installed base of Simoa instruments exceeded 1,000, with approximately 84% being the upgraded HD-X model. The company continues to expand its geographic reach, with sales efforts in North America, Europe, and various countries across Asia and the Middle East. The acquisition of Akoya has also broadened its product offerings to include spatial biology solutions, enhancing its capabilities in clinical research and diagnostics.
Looking ahead, Quanterix anticipates ongoing operating losses into 2026 as it invests in research and development, particularly for new assays and instruments. The company aims to achieve cash flow breakeven by 2026, contingent on meeting revenue and expense objectives. The management has initiated cost-reduction measures, targeting an annualized operating expense reduction of approximately $85 million, which they believe will help offset the costs associated with the recent acquisitions and support future growth.
About Quanterix Corp
Quanterix is a life sciences company specializing in ultra-sensitive digital immunoassay platforms based on proprietary Simoa technology. Its core business involves developing and selling instruments, consumables, and assay kits for protein biomarker detection in blood and fluids, serving research, biotech, and clinical markets. The company advances early disease detection, diagnostics, and biomarker research, with applications in neurology, oncology, immunology, and inflammation.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.